Rapid PD-L1 detection in tumors with PET using a highly specific peptide
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Molecular imaging can report on the status of the tumor immune microenvironment and guide immunotherapeutic strategies to enhance the efficacy of immune modulation therapies. Imaging agents that can rapidly report on targets of immunomodulatory therapies are few. The programmed death ligand 1 (PD-L1) is an immune checkpoint protein over-expressed in several cancers and contributes to tumor immune suppression. Tumor PD-L1 expression is indicative of tumor response to PD-1 and PD-L1 targeted therapies. Herein, we report a highly specific peptide-based positron emission tomography (PET) imaging agent for PD-L1. We assessed the binding modes of the peptide WL12 to PD-L1 by docking studies, developed a copper-64 labeled WL12 ([64Cu]WL12), and perform its evaluation in vitro, and in vivo by PET imaging, biodistribution and blocking studies. Our results show that [64Cu]WL12 can be used to detect tumor PD-L1 expression specifically and soon after injection of the radiotracer, to fit within the standard clinical workflow of imaging within 60 min of administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006 · cited 1×
“6, Schrödinger, LLC, New York, NY, 2016) [18].”
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“Currently, immunohistochemical (IHC) detection is the best-studied predictive biomarker for therapeutic monitoring of PD-L1/PD-1 targeted therapies [5], but this approach and its available FDA-approved diagnostic IHC tests for PD-L1 have significant limitations [6], hampered by inconsistent definitions of antigen-posi…”
BackgroundHalgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030644s · Cited by 5,177 · cited 5×
“1, Schrödinger, LLC, New York, NY, 2016) using default settings and input ring conformations [19, 20].”
BackgroundMethodInfluentialMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 3×
“Increased PD-L1 in the tumor microenvironment (TME) causes immune suppression by deactivation of immune infiltrates via binding to programmed cell death protein 1 (PD-1) receptor, expressed by active immune infiltrates [1, 4].”
BackgroundPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · cited 1×
“Increased PD-L1 in the tumor microenvironment (TME) causes immune suppression by deactivation of immune infiltrates via binding to programmed cell death protein 1 (PD-1) receptor, expressed by active immune infiltrates [1, 4].”
BackgroundMolecular imaging in drug development
Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., & Gambhir, S. S. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2290 · Cited by 1,171
Collaboration gets the most out of software
Morin, A., Eisenbraun, B., Key, J., Sanschagrin, P. C., Timony, M. A., Ottaviano, M., & Sliz, P. (2013) · eLife · doi:10.7554/elife.01456 · Cited by 1,081 · cited 1×
“Software used for these computations was curated by SBGrid [21].”
MethodStructure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531 · cited 1×
“To assess the binding mode of WL12 to PD-L1, we used the co-crystal structure of human PD-L1 bound to PD-1 (PDB ID: 4ZQK)[23] to dock WL12 in the place of PD-1.”
MethodAnderson, C. J., & Ferdani, R. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0674 · Cited by 374
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
Roach, C., Zhang, N., Corigliano, E., Jansson, M., Toland, G., Ponto, G., Dolled-Filhart, M., Emancipator, K., Stanforth, D., & Kulangara, K. (2016) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000408 · Cited by 340 · cited 1×
“Currently, immunohistochemical (IHC) detection is the best-studied predictive biomarker for therapeutic monitoring of PD-L1/PD-1 targeted therapies [5], but this approach and its available FDA-approved diagnostic IHC tests for PD-L1 have significant limitations [6], hampered by inconsistent definitions of antigen-posi…”
BackgroundHerrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167361 · Cited by 276 · cited 1×
“Peptide-based PET tracers targeting somatostatin receptors and chemokine receptor 4 (CXCR4) produce high target-to-non-target ratios in patients[16].”
BackgroundNoninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies
Heskamp, S., Hobo, W., Molkenboer-Kuenen, J. D. M., Olive, D., Oyen, W. J. G., Dolstra, H., & Boerman, O. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3477 · Cited by 234
Peptide-based imaging agents for cancer detection
Sun, X., Li, Y., Liu, T., Li, Z., Zhang, X., & Chen, X. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.007 · Cited by 224 · cited 1×
“In this regard, low molecular weight, peptide-based PET tracers are desirable candidates for clinical application due to their fast clearance and synthetic tractability[15].”
BackgroundDeng, R., Bumbaca, D., Pastuskovas, C. V., Boswell, C. A., West, D., Cowan, K. J., Chiu, H., McBride, J., Johnson, C., Xin, Y., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1136043 · Cited by 199
Pandit-Taskar, N., O'Donoghue, J. A., Durack, J. C., Lyashchenko, S. K., Cheal, S. M., Beylergil, V., Lefkowitz, R. A., Carrasquillo, J. A., Martinez, D. F., Fung, A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0552 · Cited by 195 · cited 1×
“Although radiolabeled antibody conjugates are increasingly used for imaging tumorspecific proteins, longer clearance times, extending up to days, are required for enhanced contrast and lesion detection[14].”
BackgroundHigh-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
Hettich, M., Braun, F., Bartholomä, M. D., Schirmbeck, R., & Niedermann, G. (2016) · Theranostics · doi:10.7150/thno.15253 · Cited by 194 · cited 1×
“Low uptake observed in spleen, thymus and brown fat, tissues that are known to express PD-L1 and reported to show increased radiolabeled antibody uptake [9, 11, 12], suggests that [64Cu]WL12 has very low or no affinity for mouse PD-L1, which was confirmed by in vitro and in vivo studies performed using mouse mammary c…”
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
Chatterjee, S., Lesniak, W. G., Gabrielson, M., Lisok, A., Wharram, B., Sysa-Shah, P., Azad, B. B., Pomper, M. G., & Nimmagadda, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7143 · Cited by 194 · cited 2×
“Low uptake observed in spleen, thymus and brown fat, tissues that are known to express PD-L1 and reported to show increased radiolabeled antibody uptake [9, 11, 12], suggests that [64Cu]WL12 has very low or no affinity for mouse PD-L1, which was confirmed by in vitro and in vivo studies performed using mouse mammary c…”
MethodSelf-citationPD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET
Lesniak, W. G., Chatterjee, S., Gabrielson, M., Lisok, A., Wharram, B. L., Pomper, M. G., & Nimmagadda, S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00348 · Cited by 167 · cited 2×
“Mice harboring hPD-L1 and CHO tumors with high and low PD-L1 expression (n=5), respectively were injected intravenously with 40 μCi of [64Cu]WL12 and biodistribution studies were performed as described previously [13].”
MethodSelf-citationJosefsson, A., Nedrow, J. R., Park, S., Banerjee, S. R., Rittenbach, A., Jammes, F., Tsui, B., & Sgouros, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2141 · Cited by 164 · cited 1×
“Low uptake observed in spleen, thymus and brown fat, tissues that are known to express PD-L1 and reported to show increased radiolabeled antibody uptake [9, 11, 12], suggests that [64Cu]WL12 has very low or no affinity for mouse PD-L1, which was confirmed by in vitro and in vivo studies performed using mouse mammary c…”
Cited by
Detection of cell–cell interactions via photocatalytic cell tagging
Oslund, R. C., Reyes-Robles, T., White, C. H., Tomlinson, J. H., Crotty, K. A., Bowman, E. P., Chang, D., Peterson, V. M., Li, L., Frutos, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01044-0 · Cited by 133
Yao, Y., Zhou, X., Zhang, A., Ma, X., Zhu, H., Yang, Z., & Li, N. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110200 · Cited by 10
Metadata
- Authors
- Chatterjee, S., Lesniak, W. G., Miller, M. S., Lisok, A., Sikorska, E., Wharram, B., Kumar, D., Gabrielson, M., Pomper, M. G., Gabelli, S. B., & Nimmagadda, S.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 483
- Issue
- 1
- Pages
- 258-263
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2563163619
- Cited by
- 163
- References
- 22
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.